US FDA approves first biosimilar, keeps quiet on naming standards

The US Food and Drug Administration (FDA) approved Sandoz’s cancer product Zarxio (filgrastim-sndz) on Friday (March 6)—the first biosimilar to be rubber stamped in the US.

Already registered?

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk

More on this story

Americas

Novartis win blocks generics relitigating $7.8bn heart drug patent

22 January 2026 A district court judge shuts down a Novartis rival from reopening validity and infringement arguments over an Entresto patent.

Americas

Rooted rights: Lessons from plant patent infringement and invalidity cases

22 January 2026 From public use and foreign sales to the challenges of proving infringement, plant patents present unique legal opportunities—and pitfalls—for the agricultural industry, explain Bree Vculek, Gaby Longsworth, and Robert Millonig of Sterne Kessler.

Americas

Skinny labels, big stakes: SCOTUS lines up the case of the year

21 January 2026 The court’s review of a high-profile dispute could offer clarity on a grey area for pharma companies and generic drug makers, but also prompt fresh questions.

More features

Novartis win blocks generics relitigating $7.8bn heart drug patent

Leading the arena: WIPR identifies the top US trade secrets specialists of 2025

Rooted rights: Lessons from plant patent infringement and invalidity cases

Cadwalader global head among trio moving to Orrick

Skinny labels, big stakes: SCOTUS lines up the case of the year

Chinese biotech strikes billion dollar deal in nextgen cancer race

$5.4bn medtech leader fails to bury a rival's patent

Senior four-partner team leaves A&O Shearman

US FDA approves first biosimilar, keeps quiet on naming standards

More on this story

Editor's picks

Editor's picks

More features